X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Phase III Adult Stem Cell Company Covers Ability of its COVID-19 Nutraceutical to Repair Injured Brain Cells and Stimulate Endogenous Brain Stem Cells comprising administration of green tea and/or an extract.
Lead Product(s): Green Tea Extract,Nigella Sativa Extract,Broccoli Extract
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Pervistop (Epigallocatechin Gallate) once-daily supplement provides a true alternative to eradicating the root problem of HPV persistence, which can unpredictably evolve into cancer.
Lead Product(s): Green Tea Extract,Hyaluronic Acid,Vitamin B12
Therapeutic Area: Infections and Infectious Diseases Product Name: Pervistop
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Infections and Infectious Diseases Product Name: QuadraMune
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Using a standard test for natural killer cell activity, the K562 lysis assay, 12 healthy volunteers taking one week of placebo had an average activity of 2.3 (±0.6), whereas those taking one week of QuadraMune™ had an average activity of 5.2 (±1.2), almost double.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Infections and Infectious Diseases Product Name: QuadraMune
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Psychiatry/Psychology Product Name: QuadraMune
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Pterostilbene is one of four ingredients which comprise QuadraMune™, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Neurology Product Name: QuadraMune
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company showed that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Oncology Product Name: QuadraMune
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Administration of daily doses of QuadraMune™ in healthy volunteers results in statistically significant increases in immune response activity within 5 days.
Lead Product(s): Pterostilbene,Sulforaphane,Green Tea Extract
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
